UTHR - United Therapeutics GAAP EPS of $4.91 beats by $1.10 revenue of $516M beats by $22.54M

• United Therapeutics press release ( NASDAQ: UTHR ): Q3 GAAP EPS of $4.91 beats by $1.10 .
• Revenue of $516M (+16.0% Y/Y) beats by $22.54M .
• “We are extremely pleased to have achieved several commercial milestones in the third quarter, highlighted by Tyvaso becoming our first $1 billion annual run rate product,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. “Tyvaso DPI has provided a catalyst to our growth trajectory and has us well positioned to achieve our goal of 6,000 patients on Tyvaso by the end of the year.”

For further details see: